Brii Biosciences Ltd

Brii Biosciences Limited develops therapies for infectious and central nervous system diseases in China and the United States. Its pipeline includes BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody, all in Phase 2 development for functional cure of hepatitis B. The company also develops BRII-732, which has completed Phase 1 clinical trials, and BRII-753 for the treatment of HIV. Additional candidates include Soralimixin for multi-drug resistant or extensively drug resistant (MDR/XDR) gram-negative bacterial infections, which has completed Phase 1, and Epetraborole for oral treatment of patients with treatment-refractory Mycobacterium avium complex (MAC) lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China.